IDEXX Laboratories, Inc. $IDXX Shares Bought by ING Groep NV

Posted by George Bondi on Jun 9th, 2026

ING Groep NV grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3,319.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,491 shares of the company’s stock after purchasing an additional 11,155 shares during the quarter. ING Groep NV’s holdings in IDEXX Laboratories were worth $7,774,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 58.8% in the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares in the last quarter. Wormser Freres Gestion raised its holdings in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares in the last quarter. Finally, WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.2%

Shares of IDEXX Laboratories stock opened at $561.17 on Tuesday. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $44.27 billion, a P/E ratio of 41.32, a PEG ratio of 3.08 and a beta of 1.55. The company’s fifty day moving average is $562.81 and its two-hundred day moving average is $631.11.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Piper Sandler cut their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group cut their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $751.00.

Get Our Latest Research Report on IDEXX Laboratories

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.